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While cytotoxic chemotherapy remains the hallmark
of cancer treatment, intensive regimens fall short in
many malignancies, including high-risk neuro-
blastoma. One alternative strategy is to therapeuti-
cally promote tumor differentiation. We created a
gene expression signature to measure neuroblast
maturation, adapted it to a high-throughput plat-
form, and screened a diversity oriented synthesis-
generated small-molecule library for differentiation
inducers. We identified BRD8430, containing a
nine-membered lactam, an ortho-amino anilide func-
tionality, and three chiral centers, as a selective
class I histone deacetylase (HDAC) inhibitor
(HDAC1 > 2 > 3). Further investigation demonstrated
that selective HDAC1/HDAC2 inhibition using com-
pounds or RNA interference induced differentiation
and decreased viability in neuroblastoma cell lines.
Combined treatment with 13-cis retinoic acid aug-
mented these effects and enhanced activation of
retinoic acid signaling. Therefore, by applying a
chemical genomic screening approach, we identified
selective HDAC1/HDAC2 inhibition as a strategy to
induce neuroblastoma differentiation.
INTRODUCTION
To date, cytotoxic agents have dominated the arsenal of drugs
used to treat patients with cancer. Great progress has been
made in treating patients with these compounds, but progress
has slowed and alternate approaches will be needed to continue
to advance patient care. Many cancer types have defects in both
proliferation and differentiation, with the former being the target
of current chemotherapies. Markedly less effort has gone into
identifying compounds that target the differentiation defect,
although some prodifferentiating agents have already provenChemistry & Biology 20,efficacious in the clinic. For example, all-trans retinoic acid
(ATRA) differentiation therapy has revolutionized the care of
patients with acute promyelocytic leukemia (APL) (Abdel-Wahab
and Levine, 2010; Ade`s et al., 2010). We thus embarked on the
task of identifying additional differentiation therapies.
Historically, much of phenotype-based screening has focused
on the endpoint of cell death. Screening for induction of
differentiation is a markedly more challenging task because of
the complexity of the target phenotype. In most cases, a single
marker gene cannot be used as a read-out for differentiation.
Current high-content imaging techniques have enabled screen-
ing for morphological changes. Here, however, we opted to use
gene expression-based high-throughput screening (GE-HTS), a
method that uses gene expression signatures as proxies for
biologic state switches. The gene expression signatures can
be detected in a high-throughput screening platform that
involves ligation-mediated amplification of the genes of interest
and a fluorescent bead-based detection (Peck et al., 2006;
Stegmaier et al., 2004).
At the same time, small-molecule libraries and screening
capabilities in academic centers have continued to evolve over
the past decade. In the past, standard combinatorial libraries
were largely populated by planar, achiral compounds, possibly
due to the ease with which these compounds could be made.
However, recent evidence has shown that complexity (as
measured by sp3 content) and the inclusion of chiral centers
are important factors in the transition from discovery through
drug development (Lovering et al., 2009). Indeed, many com-
pounds known to disrupt key protein-protein interactions are
structurally complex natural products (Koehn and Carter,
2005). Diversity-oriented synthesis (DOS) is a strategy that yields
collections of small molecules with structural complexity and
diversity mimicking that of natural products (Schreiber, 2000).
We thus opted to screen a DOS library of small molecules
(Marcaurelle et al., 2010). Furthermore, the DOS library selected
for screening was biased for chromatin modification by the
incorporation of moieties that bind zinc. Broad transcriptional
changes regulate differentiation, and epigenetic alterations
have been implicated in the differentiation block observed in
cancer cells (Helman et al., 2012; Lotem and Sachs, 2006;713–725, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 713
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gesting that chromatin-modifying small molecules might effec-
tively induce cellular differentiation.
For our study, we chose to look at neuroblastoma, a disease
where differentiation therapy has been successful but not yet
fully explored. Neuroblastoma is the most common extracranial
pediatric solid tumor (Modak and Cheung, 2010). Although cure
rates for patients with low-risk disease are greater than 90%, the
prognosis for patients with high-risk neuroblastoma remains
dismal, with cure rates as low as 35% despite the incorporation
of aggressive chemotherapy, surgery, radiation, transplant, and
biological therapy (Modak and Cheung, 2010). The differen-
tiating agent 13-cis retinoic acid (cisRA) is presently used to treat
minimal residual disease in the high-risk patient group after
autologous stem cell transplantation (Matthay et al., 1999). How-
ever, the full therapeutic benefit of prodifferentiating agents has
not been thoroughly explored.
Here, we report the development of a robust gene expression
signature for neuroblastoma differentiation. We screened a DOS
library for induction of the neuroblastoma differentiation signa-
ture. We identified a prodifferentiating compound, BRD8430,
and subsequently characterized it as a selective inhibitor of class
I histone deacetylases (HDACs; HDAC1 > 2 > 3). Further
investigation honed in on selective HDAC1/HDAC2 inhibition
as important in inducing neuroblastoma differentiation and cell
death.
RESULTS
A Gene Expression Signature for Neuroblastoma
Differentiation
Identifying small-molecule inducers of neuroblastoma differenti-
ation via high-throughput screening is a challenging task
because of the complexity of the target phenotype. Therefore,
we developed a gene expression signature representing differ-
entiation and adapted it for GE-HTS, a previously described
method that uses ligation-mediated amplification and fluores-
cent bead-based detection to measure gene expression levels
(Peck et al., 2006; Stegmaier et al., 2004). Two neuroblastoma
cell lines, BE(2)-C, which harbors MYCN amplification, and SH-
SY5Y, MYCN nonamplified, were treated with the prodifferenti-
ating agent(s) cisRA and/or phorbol 12-myristate 13-acetate
(PMA) or the appropriate vehicle control. Whole-genome expres-
sion analysis was then performed using Affymetrix microarrays.
A 59-gene signature for neuroblastoma differentiation was
derived; it included 40 upregulated genes in the chemically
differentiated cells relative to the undifferentiated neuroblastoma
cells, 11 downregulated genes in the differentiated cells, and 8
reference genes with stable expression across the two biological
states (see Supplemental Experimental Procedures available
online for a full description of the signature creation and Table
S1 for a list of the signature genes and probes). Two known dif-
ferentiation agents, ATRA and cisRA, were confirmed to induce
the differentiation signature in a dose-dependent manner in
BE(2)-C cells after 2 days of treatment (Figure 1A). The combined
expression of the signature genes can be represented by a single
value (i.e., the weighted summed score), which will heretofore be
referred to as the ‘‘differentiation score.’’ Absolute scores are not
directly comparable across experiments, but compound perfor-714 Chemistry & Biology 20, 713–725, May 23, 2013 ª2013 Elseviermance can be evaluated within an experiment relative to positive
and negative controls. The differentiation signature was further
validated by treating the SH-SY5Y cell line with both cisRA and
PMAand by treating three additionalMYCN amplified neuroblas-
toma cell lines not used in the development of the GE-HTS
signature (Kelly, LAN-1, and NGP) with cisRA (Figures S1A–
S1D). Finally, we confirmed in BE(2)-C cells that at doses which
induced the differentiation signature, differentiation was de-
tected by another experimental approach: immunofluorescent
labeling for the differentiation marker NF-M (neurofilament
medium; Figure S1E) in extended neurite projections.
Screening of a DOS Library Identifies an Inducer
of Neuroblastoma Differentiation
The compound library used to screen for the induction of the
differentiation signature was created through DOS (Marcaurelle
et al., 2010) and biased for chromatin modification via incorpora-
tion of a zinc-chelating ortho-amino anilide group. BE(2)-C cells
were treated in duplicate with 10 mM of 1,916 members of the
DOS library. DMSO treatment was used as the negative control,
and 1 mM of cisRA as the positive control. After incubating for
2 days, the GE-HTS assay was performed. The ability of each
compound to induce differentiation was evaluated by five com-
plementary scoring methods (Figure S1F). Their performance in
two of the five methods is shown in Figure 1B. The 32 top-
scoring compounds were selected to be rescreened across a
range of concentrations.
To confirm the activity observed in the primary screen,
eight concentrations of each compound were evaluated in
duplicate in BE(2)-C cells after 2 days of incubation. Again,
all 32 compounds induced the differentiation score at 10 mM
but differed in their overall concentration-response profiles,
with the best-performing compound, BRD8430, significantly
inducing the signature at all eight concentrations tested
and the worst-performing compound, BRD3259, significantly
inducing the signature with five of the eight concentrations
(Figures 1C and 1D). To incorporate the performance across
the full concentration range, a curve was fitted to the differentia-
tion score across the eight concentrations and the area under the
curve (AUC) was calculated (Figures S1G and S1H). BRD8430
had the highest AUC value of the 32 compounds evaluated.
Key Stereochemical and Structural Features of
BRD8430 Elucidated through Analog Testing
One advantage of working with a small molecule derived
from a DOS pathway is the ease in accessing and evaluating
stereochemical and structural variants. Therefore, we were
able to investigate features of BRD8430 that were important
for its prodifferentiating activity by evaluating stereochemical
and structural analogs using the GE-HTS assay. In addition to
the ortho-amino anilide functionality, BRD8430 contains a
nine-membered lactam, a para-ether dimethylaniline, and three
stereocenters, two within the macrocycle and one outside of
the ring (Figure 2A). BRD8430 and its stereoisomers were
synthesized as outlined in the Supplemental Experimental
Procedures and as illustrated by the scheme in Figure S2A.
The full complement of eight stereoisomers was tested across
a range of compound concentrations. The differentiation score
across the concentration range was fitted with a curve and theLtd All rights reserved
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Figure 1. A DOS Library Was Screened for the Induction of a 59 Gene Neuroblastoma Differentiation Signature
(A) BE(2)-C cells were treated with either ATRA or cisRA across a range of doses. After 48 hr, the cells were lysed and the expression levels of the 59 signature
genes (see Table S1 for gene list) were measured using GE-HTS. The heat map depicts the relative gene expression with blue denoting low expression and red
denoting high expression (fold change range:3 to 3). Four poorly performing geneswere removed from the analysis and the eight reference genes are not shown.
(B) In BE(2)-C cells, 1,916 DOS compounds were screened in duplicate. DMSO served as the negative control and 1 mM cisRA as the positive control. The
summed score and weighted summed score for each compound or control are plotted. Compounds in red were retested in the primary assay across a range of
compound concentrations.
(C and D) Dose-responsive induction of the differentiation score (weighted summed score) for the strongest and weakest performing compounds in the
confirmatory screen (i.e., BRD8430 and BRD3259, respectively). Error bars represent the mean ± SD for two replicates per compound condition, 143 1 mM cisRA
replicates, and 336 DMSO replicates. *p < 0.01, **p < 0.001 calculated using a one-way ANOVA, with Bonferroni correction, comparing each condition to DMSO.
See also Figure S1.
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HDAC1/2 Inhibitors Differentiate NeuroblastomaAUC was calculated and used as a metric of the overall
compound performance. BRD4586, which differs from
BRD8430 only at the exo-cyclic stereocenter, retained the full
differentiation-inducing activity (Figures 2B–2D; Table S2). The
six other stereoisomers displayed markedly reduced activity
(Figure 2B; Table S2).
We also assessed the differentiation-inducing activity of
two structural analogs of BRD8430: BRD6819, which contains
an eight-membered lactam; and BRD6332, which also contains
an eight-membered lactam but with an ortho-ether dimethylani-
line. BRD6819 induced the differentiation signature in a manner
similar to BRD8430, while BRD6332 exhibited greatly dampened
differentiation activity (Figures 2E and 2F). The three most active
compounds (i.e., BRD8430, BRD4586, and BRD6819) were
confirmed to induce the differentiation signature in a second
cell line, SH-SY5Y (Figures S2B–S2D).
BRD8430 Induces Differentiation and Decreases
Viability across Neuroblastoma Cell Lines
Upon the identification of BRD8430 as a top-scoring compound,
it was repurified toR95% purity (by LC/MS) and retested in four
neuroblastoma cell lines: Kelly, LAN-1, BE(2)-C, and SH-SY5Y.
BRD8430 was confirmed to induce the differentiation signature
in a concentration-dependent manner in all four cell lines atChemistry & Biology 20,both the 2 day and 5 day time points (Figures 3A and
S3). Furthermore, BRD8430 induced morphologic changes,
including neurite outgrowth, consistent with differentiation (Fig-
ure 3B). BRD8430 also reduced the viability of these four lines
after 5 days of treatment, an expected finding when neuroblas-
toma cells undergo differentiation (Figure 3C; Table S3).
BRD8430 Is a Selective HDAC Inhibitor
BRD8430 includes an ortho-amino anilide metal chelation
moiety making it a putative inhibitor of HDACs, which require
zinc atoms for their enzymatic activity. Presumably, the ortho-
amino anilide serves as the zinc-chelating moiety and the
nine-membered central ring extends to the solvent-exposed
surface-binding region of the HDAC enzyme (Bressi et al.,
2010). Indeed, in BE(2)-C cells, BRD8430 increased histone
H3 acetylation in a concentration-dependent manner after
6 hours of treatment (Figure 4A). To determine if this HDAC
inhibitory activity is required for the induction of neuroblastoma
differentiation, an analog lacking the chelation functionality,
BRD8703, was synthesized and tested in BE(2)-C cells. The
analog did not induce the differentiation signature at con-
centrations of up to 20 mM (Figure 4B). Three analogs in which
the chelation moiety was substituted also failed to induce the
signature (Figures S4A–S4C).713–725, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 715
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Figure 2. SSARs for BRD8430 Analogs
(A) The structure of BRD8430 with its three stereo-
centers denoted 1, 2, and 3. This compound has a
nine-membered lactam, para-ether dimethylaniline,
and R,SR stereochemistry (9-para; R,SR).
(B) BE(2)-C cells were treated in duplicate with eight
concentrations of BRD8430 and its seven stereo-
isomers for 2 days. Cells were then screened for
induction of the differentiation signature. The heat-
map represents AUC values calculated for each
compound, with red denoting high AUC, yellow
denoting intermediate AUC, and green denoting
low AUC.
(C and D) The signature induction for stereo-
isomers BRD8430 (9-para; R,SR) and BRD4586
(9-para; S,SR).
(E) Differentiation score for BRD6819, a structural
analog of BRD8430 with an eight-membered
lactam (8-para; R,SR).
(F) Differentiation score for BRD6332, a structural
analog of BRD8430 with an eight-membered
lactam and ortho-ether dimethylaniline (8-ortho;
R,SR). In (C–F), error bars represent the mean ± SD
of two replicates for each compound dose, 261
replicates for DMSO, and 34 replicates for cisRA
at 1 mM. *p < 0.01, **p < 0.001 calculated using a
one-way ANOVA, with Bonferroni correction,
comparing each condition to DMSO.
See also Figure S2 and Table S2.
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HDAC1/2 Inhibitors Differentiate NeuroblastomaThere are 11 zinc-dependent HDACs. To determine which are
inhibited by BRD8430, the compound was evaluated in a
biochemical HDAC activity assay (Bradner et al., 2010b).
BRD8430 was determined to inhibit HDAC1 with a half-maximal
inhibitory concentration (IC50) of 0.069 mM (95% confidence in-
terval [CI]: 0.062–0.077), HDAC2 with an IC50 value of 0.56 mM
(95% CI: 0.47–0.66), and HDAC 3 with an IC50 value of 1.3 mM
(95% CI: 1.1–1.6). Across the same concentration range, we
were not able to determine IC50 values for inhibition of the other
HDACs (Figures 4C and S4D). Ortho-amino anilides are known
to be selective binders for HDACs 1, 2, and 3 (Moradei et al.,
2007), but BRD8430 further demonstrated a narrow margin of
selectivity for HDACs 1 and 2 over HDAC3, and for HDAC1 in
particular. This observation prompted us to further investigate
the effects of selective HDAC inhibitors on neuroblastoma cell
lines.
Selective Inhibition of HDAC1 and HDAC2 Decreases
Viability and Induces Differentiation of Neuroblastoma
Cell Lines
For more than a decade, HDAC inhibitors have been known
to decrease viability and induce differentiation in neuroblastoma716 Chemistry & Biology 20, 713–725, May 23, 2013 ª2013 Elsevier Ltd All rights reservedmodels (Coffey et al., 2000, 2001; Hahn
et al., 2008; Mu¨hlethaler-Mottet et al.,
2008; Panicker et al., 2010). The majority
of these studies have focused on the
so-called HDAC pan-inhibitors, which are
small molecules that nonselectively bind
to most of the 11 zinc-dependent HDACs.
Given the intriguing HDAC-selectivity
profile observed with BRD8430, we eval-uated the ability of a diverse collection of HDAC inhibitors
with different selectivity profiles to decrease viability and
induce differentiation in neuroblastoma cell lines. This collec-
tion included pan-HDAC inhibitors (having activity against
more than HDACs 1, 2, and 3): ITF-2357 (Leoni et al., 2005),
vorinostat (Kelly and Marks, 2005), apicidin (Darkin-Rattray
et al., 1996), and BRD7914 (Jones et al., 2006); selective
HDAC1/2/3 inhibitors: MS-275 (Suzuki et al., 1999) and
CI-994 (el-Beltagi et al., 1993); selective HDAC1/2 inhibitors:
BRD5298 (Wilson et al., 2011), compound 60 (Methot et al.,
2008; Moradei et al., 2007), and BRD5100 (Wilson et al.,
2011); a selective HDAC6 inhibitor: BRD8148 (Wilson
et al., 2011); a selective HDAC8 inhibitor: PCI-34051 (Balasu-
bramanian et al., 2008); and a selective HDAC3 inhibitor: inhib-
itor 106 (Chou et al., 2008).
Two neuroblastoma cell lines, BE(2)-C and Kelly, were
treated with each inhibitor at four concentrations, and cell
viability was measured at days 2 and 5 (Figures 4D and S4E).
The selective HDAC6 and HDAC8 inhibitors did not signi-
ficantly decrease viability, and the selective HDAC3 inhibitor
only decreased viability at the highest concentration (10 mM)
at both time points. All three selective HDAC1/2 inhibitors
AC
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Figure 3. BRD8430 Induces Differentiation
and Decreases Viability in Four Neuroblas-
toma Cell Lines
(A) Concentration-dependent induction of the dif-
ferentiation score after a 5-day incubation with
BRD8430 in four cell lines. Error bars represent the
mean ± SD of four replicates. *p < 0.01, **p < 0.001
calculated using a one-way ANOVA, with Bonfer-
roni correction, comparing each condition to
DMSO. See Figure S3 for day 2 time point.
(B) BE(2)-C cells were treated with vehicle (DMSO)
or BRD8430 at the indicated concentrations and
labeled for NF-M (red) and DAPI (blue).
(C) Cells were treated with BRD8430 across a
9-point concentration range for 5 days and then
viability wasmeasured using an ATP-based assay.
The values relative to the DMSO-treated controls
are displayed with error bars representing the
mean ± SEM of four replicates. See Table S3 for
IC50 values.
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HDAC1/2 Inhibitors Differentiate Neuroblastomahad little effect on viability after 2 days of treatment but
greatly decreased viability after 5 days of treatment. In
contrast, the effects of the pan-HDAC inhibitors and the selec-
tive HDAC1/2/3 inhibitors were comparable at all time points
analyzed.
The ability of several of the compounds to induce the differ-
entiation signature in BE(2)-C cells after 2 days of treatment
was also assessed. Neither the selective HDAC6 inhibitor norChemistry & Biology 20, 713–725, May 23, 2013the selective HDAC8 inhibitor signifi-
cantly induced the signature at any of
the concentrations tested, and the selec-
tive HDAC3 inhibitor only significantly
induced the signature at the highest con-
centration (10 mM) (Figure 4E). Vorino-
stat, a pan-HDAC inhibitor, compound
60, a selective HDAC1/2 inhibitor, and
MS-275 and CI-994, both selective
HDAC1/2/3 inhibitors, all significantly
induced differentiation at multiple con-
centrations (Figure 4F). Compound 60
is a commonly used tool compound
that selectively inhibits both HDAC1 and
HDAC2. We confirmed the selective
activity profile of this compound (Fig-
ure 5A) and demonstrated that, similar
to BRD8430, compound 60 induced the
differentiation signature across multiple
neuroblastoma cell lines at multiple time
points (Figures 5B and S5). It also
decreased the viability of these cell lines
after 5 days of treatment (Figure 5C;
Table S4).
Simultaneous Genetic Knockdown
of HDAC1 and HDAC2 Inhibits
Neuroblastoma Growth and
Induces Differentiation
To confirm the sensitivity of neu-
roblastoma cell lines to HDAC1 andHDAC2 inhibition and to determine if the inhibition of
HDAC1 or HDAC2 is preferentially responsible for the ob-
served differentiation phenotype, we used small interfering
RNA (siRNA). Two cell lines, Kelly and BE(2)-C, were trans-
fected with a nontargeting siRNA pool, an siRNA pool
targeting HDAC1, an siRNA pool targeting HDAC2, or the
HDAC1 and HDAC2 targeting pools combined (Fig-
ure 6A). The differentiation signature was only induced uponª2013 Elsevier Ltd All rights reserved 717
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Figure 4. BRD8430 Is a Selective HDAC Inhibitor
(A) Immunoblot for acetylated histone H3 (AcH3) in nuclear extracts from BE(2)-C cells treated with BRD8430 or DMSO for 6 hours.
(B) The differentiation score in BE(2)-C cells treated for 2 days with BRD8703, a BRD8430 analog lacking themetal chelation functionality. Error bars represent the
mean ± SD of six replicates. See Figures S4A–S4C for additional compounds with substitutions for the chelation functionality.
(C) Effects of BRD8430 on the enzymatic activity of HDACs 1, 2, and 3. See Figure S4D for effects on the activity of HDACs 4-9. Error bars represent themean ± SD
of three replicates.
(D) Viability relative to DMSO-treated controls for BE(2)-C cells treated with one of the 12 HDAC inhibitors for 2 (top) or 5 (bottom) days. Error bars represent the
mean ± SD of four replicates. The HDACs selectively inhibited by each compound are indicated in parentheses beside each compound name in the key. A pan-
HDAC inhibitor is defined as an inhibitor of HDACs 1, 2, 3, and other HDACs. See Figure S4E for effects of the HDAC inhibitor panel on the viability of Kelly cells.
(E and F) The differentiation score of BE(2)-C cells treated for 2 days with the indicated compounds. Error bars represent the mean ± SD of four replicates for each
HDAC inhibitor dose, 72 DMSO replicates, and 24 replicates of 1 mM cisRA. (B, E, and F) *p < 0.05, **p < 0.01, ***p < 0.001 calculated using a one-way ANOVA,
with Bonferroni correction, comparing each condition to DMSO.
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HDAC1/2 Inhibitors Differentiate Neuroblastomaconcurrent knockdown of both HDAC1 and HDAC2, with
the majority of the marker genes’ expression levels
changing in the expected direction in both cell lines (Figures718 Chemistry & Biology 20, 713–725, May 23, 2013 ª2013 Elsevier6B and 6C). Simultaneous knockdown of HDAC1 and
HDAC2 also significantly decreased cell growth in both lines
(Figure 6D).Ltd All rights reserved
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Figure 5. Compound 60, a Selective HDAC1/2 Inhibitor, Induces Differentiation and Decreases Viability in Four Neuroblastoma Cell Lines
(A) Effects of compound 60 on the enzymatic activity of HDACs 1, 2, and 3. Error bars represent the mean ± SD of three replicates.
(B) Concentration-dependent induction of the differentiation score after a 5-day incubation with compound 60 in four cell lines. Error bars represent the mean ±
SD of four replicates. *p < 0.001 calculated using a one-way ANOVA, with Bonferroni correction, comparing each condition to DMSO. See Figure S5 for day
2 time point.
(C) Cells were treated with compound 60 across a range of concentrations for 5 days and then cell viability was measured using an ATP-based assay. The values
relative to the DMSO-treated controls are displayed with error bars representing the mean ± SEM of four replicates. See Table S4 for IC50 values.
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and cisRA Enhances Differentiation, Reduces Viability,
and Activates Retinoic Acid Signaling
Combining the pan-HDAC inhibitor vorinostat with cisRA was
previously shown to strongly induce differentiation and synergis-
tically affect viability (Hahn et al., 2008). To determine if the com-
bination of more selective HDAC inhibitors and cisRA is likewise
effective, Kelly and BE(2)-C cells were treated with compound 60
plus cisRA and BRD8430 plus cisRA. These combinations
caused significantly greater induction of the differentiation signa-
ture than any of the single agents (Figures 7A and S6A; Table S5),
and it had a synergistic effect on viability (Figures 7B and S6B).
The retinoic acid (RA) pathway is a reported target of HDAC in-
hibition, and the combination of a pan-HDAC inhibitor plus ATRA
synergistically activates RA signaling (Epping et al., 2007). To
determine if this pathway is targeted in neuroblastoma cells,
the activation of a RA receptor-dependent reporter, RARE3-tk-
luc, was assessed. The combinations of compound 60 plus
cisRA and BRD8430 plus cisRA displayed greater activity on
RARE3-tk-luc than the effects of any agent alone (Figures 7C
and S6C).
DISCUSSION
Neuroblastoma is the most common extracranial solid tumor of
childhood. It is a highly heterogeneous disease; some cases
resolve without intervention, while others remain refractoryChemistry & Biology 20,despite aggressive treatment with chemotherapy, surgery, radi-
ation, autologous stem cell transplantation, and consolidation
with cisRA and immunotherapy (Modak andCheung, 2010). Clin-
ically, we have reached toxicity limits in using standard cytotoxic
chemotherapy, thus alternative modalities for treating patients
with high-stage neuroblastoma are greatly needed. Differentia-
tion therapy is a strategy that has shown promise but has not
been fully explored in neuroblastoma. It has been demonstrated
that cisRA, a prodifferentiating agent, is beneficial when admin-
istered to patients with minimal residual disease following
consolidation chemotherapy and/or autologous stem cell trans-
plantation (Matthay et al., 1999). However, it has not proven
beneficial in patients with measurable disease (Kohler et al.,
2000). In another disease, APL, ATRA differentiation therapy
has been a highly effective front-line treatment (Abdel-Wahab
and Levine, 2010; Ade`s et al., 2010). Consequently, the identifi-
cation of additional differentiating agents to be used in treating
patients with neuroblastoma, either alone or in combination
with cisRA, is warranted.
However, efforts to identify these differentiation agents have
been hampered due to minimal industry interest in leading
such efforts, lack of high-throughput phenotypic assays to mea-
sure neuroblast maturation, and limited chemical diversity in
current combinatorial libraries. We sought to overcome these
challenges by integrating the screening of a structurally diverse,
small-molecule library with a gene expression-based differ-
entiation assay. We identified a 59-gene signature for the713–725, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 719
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Figure 6. Genetic Knockdown of HDAC1 and/
or HDAC2 in Neuroblastoma Cell Lines
(A) Immunoblots illustrating knockdown of HDAC1
and HDAC2 in Kelly and BE(2)-C cells 2 days after
transfection with siRNAs targeting these genes.
Control cells were transfected with pooled non-
targeting siRNAs.
(B) Differentiation score at day 4 (BE(2)-C) or day 6
(Kelly) after transfection with nontargeting siRNAs
(NT), siRNAs targeting HDAC1, siRNAs targeting
HDAC2, or the combined HDAC1- and HDAC2-
targeting siRNA pools. Error bars represent the
mean ± SEM of six replicates. ***p < 0.001 calcu-
lated using a one-way ANOVA, with Bonferroni
correction, comparing each siRNA condition to NT.
(C) Heatmaps displaying the relative expression of
the 34 differentiation signature genes changing in
the anticipated direction in both Kelly cells at day 6
posttransfection and BE(2)-C cells at day 4 post-
transfection. Blue indicates low expression and
red indicates high expression (fold change range:
3 to 3).
(D) Viability of Kelly and BE(2)-C cells relative to the
viability at the time of seeding (day 2 post-
transfection). Error bars represent the mean ± SD of
six replicates. *p < 0.05, **p < 0.01, ***p < 0.001
calculated using a two-way repeated-measures
ANOVA, with Bonferroni correction, comparing each
condition to NT at each time point.
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HDAC1/2 Inhibitors Differentiate Neuroblastomadifferentiation of neuroblastoma cells, adapted it to the GE-HTS
platform, and screened a DOS library of small molecules.
Through our screening efforts, we identified a prodifferentiating
compound, BRD8430.
The structure of BRD8430 includes a nine-membered lactam,
para-ether dimethylaniline, defined stereochemistry at three
positions, and an ortho-amino aniline functional group that
imparts HDAC inhibitory activity. The stereo/structure activity
relationship (SSAR) analysis revealed that the stereochemistry720 Chemistry & Biology 20, 713–725, May 23, 2013 ª2013 Elsevier Ltd All rights reservedat the two endo-cyclic stereocenters is
critical for BRD8430’s activity; however,
the stereochemistry at the exo-cyclic
stereocenter is not. Furthermore, the size
of the central ring can be reduced by one
atom without affecting the activity, but
changing the substitution pattern of
the dimethylaniline markedly decreased
activity. Gene expression data were thus
successfully used to detail how structural
changes to a compound influence its ability
to induce a complex phenotype.
These studies revealed that the HDAC
inhibitory activity of BRD8430 is essential
to induce the differentiation phenotype.
The acetylation status of amino acids in
histone tails dictates how tightly DNA is
wound and thus how accessible the DNA
is to transcription factors and other gene
regulatory elements (Gregory et al., 2001).
High histone acetylation is associated
with active transcription, while low histoneacetylation is associated with gene silencing. Acetyl groups are
added by histone acetyl transferases (HATs) and removed by
HDACs, which includes 18 enzymes divided into four classes
(I–IV). It is hypothesized that defects in neuroblastoma differ-
entiation are related to aberrant transcriptional regulation,
and HDAC inhibitors have previously been shown to induce
differentiation in neuroblastoma, presumably by enhancing
the active transcription of genes critical to the differentiation
program (Hahn et al., 2008). HDAC inhibitors also hold promise
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Figure 7. Combined Treatment of Selective
HDAC1/2 Inhibitors and cisRA in BE(2)-C
Cells
(A) BE(2)-C cells were treated with an HDAC in-
hibitor (compound 60 or BRD8430) and cisRA
alone and in combination for 2 days and then the
differentiation score was measured. The whiskers
indicate the maximum and minimum values of four
replicates per condition. Each condition was
significantly different from DMSO and each com-
bination was significantly different from the cor-
responding single-agent treatments; the relevant
comparisons are included in Table S5.
(B) Isobolograms of the effect of the combined
treatment of compound 60 and cisRA or BRD8430
and cisRA on the viability of BE(2)-C cells at 4 or
5 days, respectively. Each circle on the plot rep-
resents one of the compounds at a fixed dose and
the concentration of the second compound in
combination to produce 50% viability compared
to the vehicle control. Synergy appears as points
below the line of additivity.
(C) Activation of a retinoic acid signaling reporter,
RARE3-tk-luc, with compound 60 ± cisRA or
BRD8430 ± cisRA treatment in BE(2)-C cells. Dis-
playedare thenormalized values, luciferase:renilla,
relative to the ratio in the DMSO-treated control
cells. Error bars represent the mean ± SD of two
replicates for the compound 60 experiment, and
the mean ± SD of three replicates for the BRD8430
experiment. *p < 0.05, **p < 0.001 calculated using
a one-way ANOVA, with Bonferroni correction,
comparing each condition toDMSO.SeeFigureS6
for results of these experiments in a second cell
line, Kelly.
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HDAC1/2 Inhibitors Differentiate Neuroblastomaas effective anticancer agents more broadly. Indeed, the
HDAC inhibitors vorinostat and romidepsin are approved
therapies for cutaneous T-cell lymphoma (Mann et al., 2007;
Piekarz et al., 2009; Whittaker et al., 2010), and several other
HDAC inhibitors are currently in clinical trials (Rasheed et al.,
2008).
However, the present inhibitors used clinically are largely
nonspecific, having activity against multiple HDACs across one
or more classes. Vorinostat, which has been previously reported
to decrease viability and induce differentiation in neuroblastoma,
inhibits HDACs 1, 2, 3, and 6 at subnanomolar concentrations
and HDAC8 at a low micromolar concentration. BRD8430,
although a less potent inhibitor, exhibits greater selectivity for
class I HDACs (HDAC1 > 2 > 3) over all other HDACs, and it
prompted further investigation through which we uncovered
HDAC1 and HDAC2 as the critical targets for the induction
of neuroblastoma differentiation and attenuation of cellular
viability. Because the use of relatively nonselective HDAC inhib-
itors causes patient toxicity, morbidity may be mitigated byChemistry & Biology 20, 713–725, May 23, 2013increasing isoenzyme selectivity of com-
pounds. Indeed, there is a general move-
ment toward more selective, targeted
therapies for patients with cancer, such
as PI3K isoform-specific inhibitors (Kong
and Yamori, 2009) and the inhibition of
BRAF V600E by PLX4720 (Tsai et al.,2008). Moreover, there has been a call for HDAC1/2 selective
molecules for the treatment of patients with sickle cell disease
(Bradner et al., 2010a).
Combination therapy has generally been themode for curative
treatment of patients with cancer. CisRA is a logical candidate to
nominate for combination testing with selective HDAC inhibition
for patients with neuroblastoma. CisRA differentiation therapy
has already been incorporated into the standard of care for
patients with high-risk neuroblastoma, and intriguingly, in a
phase I trial evaluating vorinostat ± cisRA to treat pediatric
patients with solid tumors, the one complete response was
observed in a patient with neuroblastomawho received the com-
bination therapy (Fouladi et al., 2010).
Retinoids and HDAC inhibitors have nonindependent mecha-
nisms of action. In the absence of ligand, retinoid receptors bind
corepressors (NCoR and SMRT), which are found within a com-
plex containing HDAC activity, and mediate transcriptional
repression. When ligand bound, retinoid receptors recruit
coactivators with histone acetylase activity (HATs) leading toª2013 Elsevier Ltd All rights reserved 721
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HDAC1/2 Inhibitors Differentiate Neuroblastomaactivated transcription (Minucci and Pelicci, 1999). Thus, both
retinoic acid receptors (RARs) and HDACs are involved in the
regulation of RA target genes. A relevant clinical example of
RA receptors and HDACs acting in concert is the defining lesion
of APL (i.e., PML-RARa fusion) that blocks cellular differentiation
by recruiting the NCoR/HDAC complex and represses transcrip-
tion (Minucci and Pelicci, 1999). More recently, Epping et al.
(2007) identified RA signaling as a target of HDAC inhibitors using
a functional genetic screen. They reported that HDAC inhibition
activates RA signaling, which is repressed by the expression of
either RARa or preferentially expressed antigen of melanoma
(PRAME), a known repressor of RA signaling (Epping et al.,
2007). Moreover, they observed a synergistic induction of RAR
transactivation with the combination of ATRA and an HDAC
inhibitor in a heterologous reporter assay. Similarly, we observed
that in neuroblastoma cells, the combination of selective
HDAC1/2 and HDAC1/2/3 inhibitors plus cisRA displayed
greater activity on an RA receptor-dependent reporter than the
effects of either agent alone.
These studies reveal the power of integrating expression-
based screening with DOS chemistry to provide new biological
insights. They illuminate the role of HDAC1/2 selective inhibi-
tion in activating RAR signaling to induce neuroblastoma
differentiation. Our findings, in conjunction with other studies,
support the need to develop HDAC1/2 inhibitors for clinical
application.
SIGNIFICANCE
The intersection of genomics with chemical screening
has provided new opportunities in the search for small-
molecule perturbagens of complex biologic state switches.
We leveraged a gene expression-based screening approach
to identify compounds that induce differentiation in a
highly malignant pediatric solid tumor, neuroblastoma. The
integration of cisRA differentiation therapy into con-
solidation treatment for these pediatric patients has shown
promise, but the application of differentiation therapy
has not been thoroughly explored. Focusing on a collection
of DOS molecules, we demonstrate the success of this
chemical genomics approach in both prioritizing lead com-
pounds for inducing neuroblastoma differentiation and as
a read-out in SSAR evaluation. This screen identified
BRD8430 as a prodifferentiating agent. BRD8430 was
characterized as a class I HDAC inhibitor (HDAC1 > 2 > 3).
Through investigation of more selective compounds,
HDACs 1 and 2 were demonstrated to be the key targets
for induction of differentiation in neuroblastoma. Further-
more, the combination of a selective HDAC1/2 inhibitor
and cisRA had an augmented effect on differentiation and
a synergistic effect on viability, with enhanced activation of
retinoic acid signaling as a contributing mechanism to the
observed synergy. The HDAC inhibitors currently used clin-
ically are largely pan-inhibitors, having activity against many
of the 11 zinc-dependent HDACs. This work supports the
need to develop selective HDAC1/2 inhibitors for clinical
application and, more broadly, illuminates the power of inte-
grating expression-based screening with DOS chemistry to
provide new biological insights.722 Chemistry & Biology 20, 713–725, May 23, 2013 ª2013 ElsevierEXPERIMENTAL PROCEDURES
Cell Culture and Viability Assays
Neuroblastoma cell lines were maintained in DMEM (Cellgro, Manassas, VA,
USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis,
MO, USA) and 1% penicillin-streptomycin with glutamine (Cellgro). BE(2)-C
and SH-SY5Y were obtained from the American Type Culture Collection,
and Kelly and LAN-1 were kindly provided by Dr. Rani George. The identity
of all lines was verified by small tandem repeat profiling performed by the
Shannon McCormack Advanced Molecular Diagnostics Laboratory at the
Dana-Farber Cancer Institute (Boston, MA, USA). Cellular viability was
assessed using CellTiter Glo (Promega, Madison, WI, USA) per the manufac-
turer’s instructions.
Compounds
ATRA, cisRA, PMA, and VPA were purchased from Sigma-Aldrich. Compound
60 was synthesized by Dr. Jun Qi. DOS compounds were synthesized by the
Broad Institute Chemical Biology Platform; synthetic protocols are included in
Supplemental Experimental Procedures. Compounds included in the panel of
nonselective and selective HDAC inhibitors (ITF-2357, vorinostat, apicidin,
BRD7914, MS-275, CI-994, BRD5298, compound 60, BRD5100, BRD8148,
PCI-34051, and inhibitor 106) were provided by the Broad Institute Chemical
Biology Platform and Stanley Center for Psychiatric Research.
Gene Expression-Based High-Throughput Screening
Gene expression-based high-throughput screening (GE-HTS) studies were
performed as previously described (Peck et al., 2006; Stegmaier et al.,
2004), including mRNA capture, reverse transcription, ligation-mediated
amplification of the signature genes, and fluorescent bead-based detection
(FlexMap Technology, Luminex, Austin, TX, USA). Probe sequences for the
59 neuroblastoma signature genes are included in Table S1. Signature perfor-
mance was primarily evaluated using a weighted summed score (differentia-
tion score) metric, calculated by dividing the expression levels of the signature
genes by the mean expression of the control genes and then summing
the ratios with weights and signs determined by the signal-to-noise ratio of
cisRA-treated positive controls and DMSO-treated negative controls. As
with other expression profiling platforms, scores can differ across experiments
secondary to multiple features, including instrument variability, the dynamic
nature of transcriptional alterations, and the bidirectional nature of the changes
measured. Furthermore, genes that perform poorly in control conditions are
omitted from the analysis on an experiment-by-experiment basis, leading to
variation in the signature assessed. Finally, data from the low-throughput
GE-HTS experiments did not undergo the same normalization as data from
the larger screens, leading to variability in the absolute differentiation scores
between experiments.
DOS Library Screen
BE(2)-C cells were plated at 2,000 cells per well in 384-well plates with 2 nM
cisRA added as a differentiation enhancer; 1,916 compounds from the DOS
library were added in duplicate by pin transfer to a final concentration of
10 mM. Each plate included 32 wells treated with 1 mM cisRA as the positive
control and 32 wells treated with DMSO as the negative control. In addition,
a control plate with a cisRA dose response was included in each run. After
2 days of incubation, the GE-HTS assay was performed.
The screen data were analyzed as follows. The control gene N4BP1 was
used to eliminate poorly performing wells from the analysis. For the plate-
by-plate analysis, we removed wells with an N4BP1 level greater than three
median absolute deviations (MADs) from the median N4BP1 value of the
DMSO-treated wells in that plate. For median-scaling analysis, we removed
wells with an N4BP1 level greater than two MADs from the median N4BP1
value of the DMSO-treated wells across all the plates from each run. We
then made a ratio of each marker gene to the mean of the eight reference
genes within that well. For median-scaling analysis, plate-to-plate variability
was corrected by median scaling. We normalized all of the plates by scaling
each up- and downregulated gene independently based on its median expres-
sion in the cisRA-treated and DMSO-treated wells, respectively, on each plate.
The summed scores (sum of the expression ratios with the sign determined by
the expected direction of regulation) were individually transformed into robustLtd All rights reserved
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wells together, including either all of the wells in a plate (plate-by-plate anal-
ysis) or all of the wells in a run (median-scaling analysis). To identify initial
hits, we selected compounds for which both replicates had a robust Z score
higher than three. Five additional metrics were used to identify prodifferenti-
ating compounds: summed score, weighted summed score, K-nearest
neighbor, naive Bayes, and support vector machine (Hahn et al., 2009).
Thirty-two DOS compounds were selected to be retested at eight concen-
trations in duplicate in BE(2)-C cells with 2 nM cisRA as a differentiation
enhancer, 1 mM cisRA as the positive control (32 wells per plate) and DMSO
as the negative control (36 wells per plate). A control plate with a cisRA dose
response was included in each run. The GE-HTS assay was performed after
2 days of incubation. The data were analyzed as described previously.
Area under the Curve Calculation
To quantize the relative efficacy of the compounds, total activity was sum-
marized using the AUC, defined as the area between the response curve
and the zero score level (defined by the average differentiation score in
DMSO-treated negative control wells). AUC was calculated using the R
system for statistical computing (R Development Core Team, 2006; http://
www.R-project.org) by taking the cubic natural spline for 50 points spread
evenly across the log-dose curve, summing up the areas of the 49 trapezoids
formed between the 50 spline points and the zero response line, and normal-
izing the value by dividing by the range of log concentrations. Because the
AUC is a measurement summarizing the differentiation score across a
concentration range, absolute AUC values suffer the same challenges as
the differentiation score and cannot be compared directly between experi-
ments, but can be used within an experiment to assess the relative activity
of compounds.
Protein Extraction and Immunoblotting
For whole cell protein extraction, cells were lysed with Cell Signaling Lysis
Buffer (Cell Signaling Technology, Danvers, MA, USA) containing complete,
EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany) and PhosSTOP phosphatase inhibitor (Roche Diagnostics). Nuclear
protein extractions were performed using the cytoplasmic and nuclear extrac-
tion kit from Thermo Scientific (Rockford, IL, USA). Immunoblots were run as
previously described (Banerji et al., 2012). Primary antibodies included
anti-HDAC1 (Abcam ab7028, Cambridge, MA, USA), anti-HDAC2 (Abcam
ab7029), anti-Vinculin (Abcam ab18058), and anti-acetylated histone H3
(Millipore 06-599, Billerica, MA, USA).
HDAC Activity Assay
HDAC1-9 activity was determined in vitro using an optimized homogenous
assay performed in a 384-well plate (Bradner et al., 2010b). Compound was
incubated with recombinant, full-length HDAC protein (BPS Biosciences,
San Diego, CA, USA) for 3 hr prior to enzymatic reactions. The reactions
were carried out with fluorophore conjugated substrate, MAZ1600 and
MAZ1675, at Km = [S] (MAZ1600: 21 mM for HDAC1, 22 mM for HDAC2,
9 mM for HDAC3, 9 mM for HDAC6; MAZ1675: 10 mM for HDAC4, 40 mM for
HDAC5, 22 mM for HDAC7, 282 mM for HDAC8, and 26 mM for HDAC9). Reac-
tions were performed in assay buffer (50 mM HEPES, 100 mM KCl, 0.001%
Tween-20, 0.05% BSA, 200 mM TCEP, pH 7.4) and followed for fluorogenic
release of 7-amino-4-methylcoumarin from substrate upon deacetylase and
trypsin enzymatic activity. Fluorescence measurements were obtained every
5 minutes using a multilabel plate reader and plate stacker (Envision; Perkin-
Elmer, Waltham, MA, USA). Each plate was analyzed by plate repeat, and
the first derivative within the linear range was imported into analytical software
(Spotfire DecisionSite andGraphPad Prism). Replicate experimental data from
incubations with inhibitor were normalized to DMSO controls ([DMSO] <
0.5%). IC50 is determined by logistic regression with unconstrained maximum
and minimum values.
Immunofluorescence
BE(2)-C cells were treated in duplicate with either vehicle (DMSO) or the
indicated compound concentration. After 72 hr, cell were washed, fixed (4%
formaldehyde), permeabilized (0.2% Triton X-100), and stained with a
monoclonal antibody to NF-M (Santa Cruz Biotechnology sc20013) andChemistry & Biology 20,species-specific secondary antibody linked to Alexa Fluor 568 (Invitrogen,
Carlsbad, CA, USA). Slides weremountedwith Prolong Gold antifade reagents
and counterstained with DAPI (Invitrogen).
siRNA Studies
BE(2)-C and Kelly cells seeded in six-well plates were transfected with
siGENOME SMARTpool siRNAs from Dharmacon targeting HDAC1 (Thermo
Scientific M-003493-02-0005), HDAC2 (Thermo Scientific M-003495-02-
0005), or a negative control, nontargeting siRNA pool (Thermo Scientific
D-001206-13-05) following the manufacturer’s protocol. Briefly, we used 4 ml
of Dharmafect Transfection Reagent I (Thermo Scientific T-2001) per well
and a final concentration of 45 nM siRNA. After 48 hr, cells were harvested,
counted, and replated in 384-well plates for viability and GE-HTS assays.
Protein was collected to evaluate knockdown.
Dual Reporter Assay
BE(2)-C or Kelly cells were cotransfected with RARE3-tk-luc (de The´ et al.,
1990) (kindly provided by Dr. Daniel G. Tenen) and pUbC-RL plasmids using
Fugene 6 transfection reagent per the manufacturer’s instructions (Roche).
In the compound 60 experiments, the cells were harvested, counted, and
replated in a 96-well plate 24 hr posttransfection, and then compounds were
added. In the BRD8430 experiments, the cells were transfected in 96-well
plates and thus were not replated before compound addition. Twenty-four
hours later, levels of firefly luciferase and renilla luciferase were detected using
the Dual Luciferase Reporter Assay System (Promega).
Statistical Analyses
Statistical significance was determined by one-way ANOVA with Bonferroni
correction when comparing more than two unmatched groups, and by two-
way repeated-measures ANOVA with Bonferroni correction when comparing
more than two unmatched groups over a time course. Analyses were done
in GraphPad Prism 5.
ACCESSION NUMBERS
The GEO accession number for the genome-wide expression profiling data
reported in this paper is GSE45587.
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